CYTO-102

N/A

Report date: 2025/06/27 20:00:57

Base Information

Drug NameCYTO-102
Drug Alias NameCI-NKCYTO-NK-102CYTO-102COH06
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionInterleukin-15 modulatorsAnti-Programmed death-ligand 1
TargetsInterleukin-15Programmed death-ligand 1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungLung Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCytoImmune Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity of California IrvineCity Of Hope National Medical Center
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungLung Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A